Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated Identification of a subpopulation of macrophages in mammary tumor-bearing mice that are neither M1 nor M2 and are less differentiated Abstract Systemic and local immune deficiency is associated with cancer, and the role of M2 tumor-associated macrophages in this phenomenon is well recognized. However, the immune status of macrophages from peripheral compartments in tumor hosts is unclear. Peritoneal macrophages (PEM) are derived from circulating monocytes and recruited to the peritoneal cavity where they differentiate into macrophages.
Introduction
Systemic immune deficiency in cancer (1) (2) (3) and the occurrence of a local immune suppression within tumors (4, 5) have been well documented. Indeed, tumor-associated macrophages (TAM), myeloid-derived suppressor cells (MDSC) and some T-cell subsets colonizing the tumor microenvironment exhibit immunosuppressive properties. However, the contribution of macrophages from extra-tumor sites to the host immune competence has received less attention.
Circulating monocytes differentiate into macrophages upon entry into tissues. Macrophages (6) produce inflammatory cytokines to activate the adaptive immune system and aid in the elimination of microbes and tumor cells. When tissue damage is unresolved, chronic inflammation establishes (7) . In this scenario, macrophages continue to exhibit proinflammatory features and generate tissue damage indefinitely.
Two opposite polarization states have been described for macrophages depending on their immune competence: the classically activated M1 and the alternatively activated M2 (5) . The M1 macrophage is proinflammatory and is induced by IFN-g alone or together with microbial stimuli (i.e., LPS). They present antigens efficiently, produce high levels of proinflammatory cytokines such as interleukin (IL)-12, are efficient activators of Th1 T-cell responses, and are cytotoxic against microbes and tumor cells. M1 macrophages are thus considered powerful effectors against the attack of pathogens and tumor cells. M2 macrophages, in contrast, are induced by IL-4 and IL-13, immune complexes, IL-10 or glucocorticoids. They possess less efficient antigen-presenting capacity, have an IL-12 low IL-10 high phenotype, suppress Th1 immunity, and promote wound healing, tissue remodeling, and angiogenesis. Thus, M2 macrophages play a role in the homeostatic mechanisms that terminate inflammatory responses.
Substantial experimental and epidemiologic evidence links chronic inflammation with cancer (7, 8) . Macrophages are involved both in initial and later stages of carcinogenesis, paralleling the interplay between inflammation and cancer in their switch from activated M1 in inflamed tissues to M2 tumor-promoting, proangiogenic TAMs (5, 9) .
Peritoneal macrophages (PEM) are derived from circulating monocytes and represent peripheral cells exposed to the circulation in the peritoneal cavity. In contrast, TAMs differentiate within the immunosuppressive tumor microenvironment. We have shown that macrophages from mice bearing advanced D1-DMBA-3 mammary tumors (T-PEM) function less efficiently as antigenpresenting cells compared with macrophages from normal animals (N-PEMs; ref. 10) and produce low levels of IL-12 and nitric oxide (11, 12) . Moreover, a deficiency in proinflammatory functions is associated with decreased expression of transcription factors nuclear factor nB (NFnB) and CAAT/enhancer-binding protein (C/EBP) in these cells (13) . We now provide evidence that T-PEMs are neither M1 nor M2, are more prone to apoptosis, and express lower levels of macrophage differentiation markers. Furthermore, we show for the first time that macrophage depletion is associated with enhanced generation of macrophage precursors in the bone marrow.
Materials and Methods
Animals, cell lines, and tumors. BALB/c mice, 10 to 14 weeks of age, were used. D1-DMBA-3 mammary adenocarcinoma and DA-3 mammary tumor cell line, derived from D1-DMBA-3, were maintained and used as previously described (14, 15) . Lewis lung carcinoma (LLC), Renca renal cell carcinoma, 4T1 mammary carcinoma, and mouse fibroblast 3T3 cell lines were kindly provided by Eckhard Podack (University of Miami, Miami, FL). The institutional animal care and use committee approved the animal experiments.
Macrophage collection and culture. Normal and 4-wk tumor-bearing mice were injected i.p. with 1.5 mL of 3% thioglycolate (Difco Laboratories). On day 4, PEMs were obtained and cultured as described (13) .
Laser confocal microscopy. Macrophages were adhered to glass slides and Fc receptors blocked using mouse CD16/32 antibody Figure 1 . NFnB and C/EBP are down-regulated in T-PEMs. A, confocal images of N-PEMs and T-PEMs stained with NFnBp50-PE and NFnBp65-PE (red ) and with DAPI (blue ). B, NFnBp105, RelA, and c-Rel mRNA levels in N-PEMs and T-PEMs were determined by real-time PCR using 18S for normalization. C, gene expression array and densitometry shows C/EBPh mRNA expression in N-PEMs and T-PEMs using h-actin for normalization. D, Western blot of NFnB and C/EBP expression in N-PEMs and T-PEMs isolated from Renca and 4T1 tumor-bearing mice. (eBioscience). Cells were washed, fixed with 10% formalin, permeabilized with Optimax permeabilization buffer (Sigma-Aldrich) and then incubated with 4 ¶,6-diamidino-2-phenylindole (DAPI; Invitrogen) to reveal nuclei. For intracellular NFnB staining, fixed and permeabilized macrophages were incubated with NFnBp50-PE and NFnBp65-PE (Santa Cruz Biotechnologies) or with the corresponding isotype control. Fixed cells were then stained with F4/80PE-Cy7 (BioLegend), CD11b-AF488 and Gr-1-AF647 (eBioscience), incubated with DAPI, and then mounted. Slides were analyzed using a Zeiss laser scanning confocal microscope 500 (Zeiss).
Flow cytometry. N-PEMs and T-PEMs were gently scraped from tissue culture plates, washed, and counted. Fc receptors were blocked and cells were stained with CD11b-FITC, CD115-PE, Gr-1-APC antibodies (all from eBioscience), and F4/80-PE Cy7 (BioLegend). Intracellular staining for CD68-AF700 (AbD Serotec) was performed following the instructions of the manufacturer. To assess viability, cells were stained with 7-amino-actinomycin D (7-AAD; BD PharMingen), which was added 15 min prior to analyzing by flow cytometry. Samples were acquired in a LSR II cytometer (BD Biosciences).
Committed progenitor assay. Colony-forming unit (CFU) assays using stimulation with IL-3 or M-CSF (Peprotech) were performed (16) . Single clusters containing more than 50 cells were counted as a colony. Results are expressed as CFU-IL-3 and CFU-M-CSF per 10 6 cells plated. Real-time PCR. PEMs (10 7 cells) from individual normal and tumorbearing animals were cultured in complete medium without LPS (NFnB experiments) or with 10 Ag/mL of LPS for 2 h (CXCL10 experiments). Total RNA was isolated and cDNA synthesis was performed (1 Ag total RNA) using Invitrogen reagents according to the manufacturer's instructions. Real-time or quantitative PCR was done using TaqMan Gene Expression Assays for NFnBp105, relA, c-rel, CXCL10, and eukaryotic 18S RNA on a 7500 Fast Real-time PCR system from Applied Biosystems following the instructions of the manufacturer.
cDNA arrays. Relative mRNA expression was analyzed by microarray technology using the mouse JAK/signal transducer and activation of transcription (STAT) signaling pathway (MM-039) and the mouse mitogenactivated protein kinase (MAPK) signaling pathway (MM-017; GE Array Q Series, SuperArray, Inc.), using total RNAs isolated from N-PEMs and T-PEMs as previously described (17).
Antibody array. The Mouse Inflammation Antibody Array 1.1 (RayBiotech, Inc.) was used to study the expression of proinflammatory cytokines in whole cell lysates from LPS-activated (Sigma-Aldrich) N-PEM and T-PEMs, following the manufacturer's instructions.
TUNEL assay. The DeadEnd Colorimetric Terminal uridine deoxynucleotidyl transferase dUTP nick end-labeling or TUNEL System from Promega was performed according to the manufacturer's instructions, using resting N-PEM and T-PEM.
Western blot. N-PEM and T-PEM ( 10 7 ) were adhered to plastic tissue culture dishes, whole cell extracts were obtained, and Western blot was performed as previously described (13) . Rabbit a-mouse polyclonal antibodies (except for IRAK-M, a goat anti-mouse polyclonal antibody) from Santa Cruz Biotechnologies were used as the primary antibody. Anti-Bcl-x was kindly provided by Dr. Larry Boise (Department of Microbiology and Immunology, University of Miami School of Medicine, Miami, FL; ref. 18) , and staurosporine was from EMD Biosciences. Rabbit a-mouse STAT and phosphorylated STAT (STAT1 and STAT3) antibodies and a-caspase 3 antibody were from Cell Signaling Technologies. Rabbit a-mouse actin polyclonal antibody was obtained from Sigma-Aldrich. Goat a-rabbit IgG-HRP, except for the IRAK-M (rabbit a-goat IgG-HRP) was used as the secondary antibody. In some experiments, N-PEMs were pretreated with phosphatidylserine (Avanti Polar Lipids), transforming growth factor-h (TGFh), vascular endothelial growth factor (VEGF), prostaglandin E 2 (PGE 2 ), granulocyte macrophage colonystimulating factor, and IL-11 (all from Peprotech).
Macrophage depletion using liposome-encapsulated clodronate (Clodrolip). Normal mice were injected i.p. with 1 and 2 mg/20 g weight 
Results
T-PEMs express diminished levels of NFKB and C/EBP at mRNA and protein levels. Our previous studies using Western blot and EMSA revealed that resting and LPS-activated T-PEMs exhibit decreased levels and binding activities of transcription factor proteins NFnBp50, p65, c-rel, and C/EBPa and C/EBPh (13) . Down-regulation of NFnBp50 and p65 proteins in these cells was confirmed using intracellular staining and laser confocal microscopy (Fig. 1A) . We examined whether NFnB down-regulation was also reflected at the mRNA levels in T-PEMs. Real-time PCR confirmed that the mRNAs encoding for NFnBp50, p65, and c-rel proteins are down-regulated in T-PEMs (Fig. 1B) . Moreover, gene microarray experiments ( Fig. 1C ; C/EBPa was not assessed in the microarray) corroborated the decreased levels of C/EBPh transcription factor protein in T-PEMs, which we have previously described (13) . These results suggest that the factors responsible for NFnB and C/EBP diminished expression in T-PEMs may act through transcriptional or posttranscriptional mechanisms. To analyze whether this might be a more general mechanism existing in T-PEMs, we studied the protein expression of NFnB and C/EBP in T-PEMs from other mouse tumor models. Our results (Fig. 1D) , using T-PEMs from mice bearing Renca renal cell carcinomas and 4T1 mammary tumors, confirm the decreased protein expression of NFnB and C/EBP in these models.
T-PEMs are defective in the production of several proinflammatory cytokines. A major factor contributing to proin- Peritoneal Macrophages and Immune Suppression in Cancer www.aacrjournals.org 4805 flammatory impairment in T-PEMS is their diminished expression of NFnB and C/EBP. We thus hypothesized that in addition to IL-12 and nitric oxide synthase (iNOS), other inflammatory molecules transcriptionally regulated by NFnB may also be down-regulated in T-PEMs. Protein microarray analysis ( Fig. 2A) using cell lysates of LPS-activated N-PEMs and T-PEMs revealed that T-PEMs, in addition to IL-12, are deficient in the production of IL-1h, IL-6, tumor necrosis factor-a, MCP-1, and M-CSF. Interestingly, LPSactivated T-PEMs did not up-regulate expression of the antiinflammatory cytokine IL-10 compared with N-PEMs (13) . Cell viability of cultured N-PEMs and T-PEMs as determined by DAPI and PI showed no significant lethality (PI + cells) in either cell type upon cell culture (Fig. 2A) .
IRAK-1, NIK, and critical MAPK are reduced, whereas IRAK-M is increased in T-PEMs. Because different signaling pathways are involved in the control of cytokine expression, we analyzed other proinflammatory signaling pathways in T-PEMs. Several crucial intermediates operate upstream of NFnB in the Toll-like receptor/NFnB signaling pathway. Although MyD88 and IRAK-1 are important in the signaling cascade triggered by activation of Toll-like receptors on the cell surface (20) , IRAK-M is an inhibitor of this pathway (21) . Analysis of the protein expression of these intermediates in T-PEMs showed that, although there are no significant changes in the expression of MyD88 in T-PEMs, kinase IRAK-1 is dramatically diminished whereas the inhibitor kinase IRAK-M is up-regulated in T-PEMs (Fig. 2B) . Because MAPKs also play an important role in the regulation of proinflammatory cytokine gene expression (22) , their levels were analyzed in T-PEMs. Gene microarray analysis using total RNA obtained from N-PEMs and T-PEMs showed a general decrease in the mRNA expression of most of the MAPKs examined (Fig. 2C) . Furthermore, a substantial reduction of NIK (NFnB-inducing kinase), JNK, p38, and ERK1/2 gene expression was observed. These data indicate major dysfunctional signaling in several pathways of proinflammatory cytokines in T-PEMs.
STAT1, but not STAT3, is down-regulated in T-PEMs. STATs are transcription factors that regulate many aspects of cell growth, survival, and differentiation. STAT1 is involved in up-regulating genes upon stimulation by IFNs, and is associated with the activation of a Th1-type of antitumor immune response (23) . In contrast, STAT3 is overexpressed in tumor cells and is an antiapoptotic factor that leads to tumor tolerance in the host (24) . Up-regulation of the STAT3 pathway leads to increased angiogenesis, tumor survival, and immunosuppression (25) . We investigated whether T-PEMs exhibit altered expression of STAT1 and STAT3. Because these transcription factors are activated by phosphorylation, the expression of both their resting and activated (phosphorylated) forms was compared in N-PEMs and T-PEMs using Western blot analysis. As seen in Fig. 2D, STAT1 is downregulated in resting as well as LPS-activated T-PEMs. Accordingly, these cells also exhibit reduced STAT1 phosphorylation upon LPS activation compared with their normal counterparts. Interestingly, the levels of STAT3 or pSTAT3 were similar in the two cell types. We examined whether STAT1-regulated genes were also affected. Thus, the expression of the chemokine CXCL10 in LPS-stimulated N-PEMs and T-PEMs was determined. Real-time PCR analysis showed decreased CXCL10 mRNA expression in LPS-stimulated T-PEMs (Fig. 2D) .
T-PEMs express low levels of Bcl-x and high levels of activated caspase 3 and are more apoptotic. NFnB, in addition to promoting the described pathways, also induces the expression of several antiapoptotic genes such as Bcl-x. Using Western blots (Fig. 3A) , a substantial down-regulation in Bcl-x protein expression was observed in resting T-PEMs. Furthermore, TUNEL assays confirmed higher levels of apoptosis in T-PEMs, and apoptotic nuclei in these cells were pyknotic and fragmented (Fig. 3A) . Activation of caspase 3 is crucial for apoptosis. Thus, we determined whether the increased apoptosis was associated with higher levels of activated caspase 3 in T-PEMs compared with N-PEMs. Treatment with increasing concentrations of staurosporine, an apoptosisinducing agent, was included as a positive control of caspase 3 activation in N-PEMs. Results showed an increase in the basal expression of the 17 to 19 kDa bands (activated caspase 3) in T-PEMs, even at higher levels than those observed in staurosporinetreated N-PEMs, indicating caspase 3 activation and thus apoptosis execution in T-PEMs (Fig. 3B) . Consequently, T-PEMs are not only dysfunctional but may be less frequent because of their greater susceptibility to apoptosis.
Macrophage apoptosis in the periphery is associated with increased myeloid progenitors in the bone marrow of tumorbearing mice. Because our results suggest that the tumor induces decreased NFnB expression and enhanced apoptosis in T-PEMs, a compensatory increase in the generation of myeloid progenitors may be occurring in the bone marrow of tumor bearers. Thus, functional CFU assays for marrow-derived myeloid progenitors from normal and tumor-bearing mice were carried out using IL-3 and M-CSF. Our results confirm that the numbers of different myeloid progenitors are significantly increased in tumor hosts when compared with normal mice (Fig. 3C) . To determine whether decreased numbers of peripheral macrophages contribute to the induction of marrow myelopoiesis, normal mice were treated with i.p. injections of Clodrolip, a macrophage-depleting agent (19) . Flow cytometry analyses showed that treatment of normal mice with 1 or 2 mg of Clodrolip ( for 24 and 48 hours) significantly depleted F4/80 + resident PEMs, compared with PBS-treated animals at all dose combinations (Fig. 3D) . Importantly, marrow cells from these macrophage-depleted animals exhibited significantly enhanced production of CFU-M-CSF but not CFU-IL-3-induced myeloid progenitors after treatment with Clodrolip for 48 hours. Thus, 48 hours of macrophage depletion was sufficient to induce myelopoiesis in the bone marrow (Fig. 3D) . These results suggest that macrophage depletion is associated with a specific increase in marrow progenitors committed to macrophage but not other myeloid lineages.
T-PEMs down-regulate expression of F4/80, CD68, CD115, and CD11b and up-regulate Gr-1. Macrophages normally express the myeloid markers F4/80, CD68, CD115 (M-CSF receptor), and CD11b, and the elevated expression of these molecules is considered indicative of macrophage differentiation (26, 27) .
T-PEMs express significantly lower levels of F4/80, CD68, CD115, and CD11b than N-PEMs (Fig. 4A) , consistent with the phenotype of newly recruited blood monocytes (F4/80 low CD68 low C-D115 low CD11b low ). These results suggest that T-PEMs are less-differentiated than N-PEMs. Interestingly, T-PEMs also exhibit up-regulation of the granulocytic myeloid marker Gr-1. Yet, they appear as a homogeneous cell population of macrophages of larger size and increased vacuolation (Fig. 4B) . As T-PEMs are prone to apoptosis, 7-AAD viability marker was included in our flow cytometric experiments. Similar to Fig. 4A , expression of macrophage markers was decreased whereas Gr-1 expression was increased on viable (7-AAD À ) T-PEMs (Fig. 4C) . In vitro pretreatment of N-PEMs with supernatants from tumor cell lines mimics the reduced expression of NFnB and C/EBP observed in T-PEMs. Because the presence of advanced mammary tumors results in a profound decrease in expression of NFnB and C/EBP at the gene and protein levels in T-PEMs, we investigated whether ex vivo pretreatment of N-PEMs with supernatants collected from 4-day-old cultures of the DA-3 cell line produced similar effects. Figure 5A shows diminished expression of NFnB and C/EBP proteins in T-PEMs as a positive control to compare with the effect of the in vitro treatment of N-PEMs with tumor supernatants. Culturing N-PEMs with increasing concentrations of DA-3 cell supernatant induced reductions in the amounts of some NFnB and C/EBP proteins in these macrophages (Fig. 5B) . To assess whether NFnB and C/EBP down-regulation is associated with tumor-secreted factors, N-PEMs were pretreated with supernatants from different cell lines. Pretreatment of N-PEMs with supernatants from the tumorigenic LLC cell line down-regulated the expression of NFnB and C/EBP (Fig. 5C ), whereas N-PEMs pretreated with supernatants from the nontumorigenic 3T3 cell line did not (Fig. 5D ), implicating factors secreted by tumor cell lines in NFnB and C/EBP down-regulation. Cell viability of N-PEMs cultured with 80% of DA-3 and LLC cell supernatants was assessed by PI staining. No significant toxicity (increased numbers of PI + cells) was observed in these treated cells (Supplemental Fig. S1 ). Furthermore, expression of F4/80, CD11b, and Gr-1 did not change significantly when N-PEMs were cultured with LLC supernatants compared with untreated N-PEMs (Supplemental Fig. S2 ).
TGFB and PGE 2 tumor factors are associated with the diminished expression of NFKB and C/EBP observed in T-PEMs. The DA-3 tumor cell line secretes several factors (1, 15, 28, 29) which are also produced by other tumors (30, 31) . Pretreatment of N-PEMs with tumor-derived factors results in diminished expression of IL-12 and of iNOS (11, 32) . To examine whether some of these tumor-derived factors might be associated with the impairment of NFnB and C/EBP expression observed in T-PEMs, resting N-PEMs were pretreated with increasing concentrations of these tumor-derived products. Pretreatment of N-PEMs with increasing concentrations of TGFh and PGE 2 resulted in a substantial decrease in NFnB and C/EBP expression in these cells (Fig. 6A) . However, the addition of phosphatidylserine, GM-CSF, or IL-11 did not alter their expression (data not shown). Interestingly, pretreatment of N-PEMs with VEGF resulted in enhanced expression of NFnB and C/EBP. To study the possible interactions between TGFh and PGE 2 that might occur within macrophages in vivo, we pretreated N-PEMs with these tumor factors simultaneously. Our results show that these two tumor factors operate in a synergistic fashion to decrease the expression levels of NFnB and C/EBP (Fig. 6B) . (34, 35) , such as higher expression of VEGF, matrix metalloproteinase-9, or arginase (data not shown). We have previously shown that T-PEMs do produce elevated levels of the suppressor cytokine TGFh (29) . We now provide evidence that these cells display a mixed phenotype (neither M1 nor M2), with down-regulation of several proinflammatory signaling pathways and cytokine production. Potent levels of circulating tumor factors may interact with T-PEMs, leading to such a phenotype. Immune modulation may occur in the circulation when they are still monocytes, or perhaps during their differentiation to macrophages in the peritoneal cavity. The fact that both NFnB and C/EBP are constitutively decreased in these cells results in their deficiency to produce inflammatory cytokines and chemokines, such as IL-12, IL-6, tumor necrosis factor-a, IL-1h, M-CSF, and MCP-1 (36, 37) . Furthermore, the down-regulation of NIK mRNA in resting T-PEMs and the involvement of this kinase in both the classic (38) and the alternative (39) NFnB activation pathways, together with the deficiency of T-PEMs in p38, JNK, and ERK, indicate critical impairments in NFnB and related signaling pathways in these cells. STAT1, another crucial signaling mediator of Th1 immunity, is also impaired in T-PEMs. Resting or LPS-activated T-PEMs exhibit lower levels of STAT1 and pSTAT1 expression compared with N-PEMs. Moreover, the STAT1-induced gene CXCL10 was also down-regulated at the mRNA level. In contrast with our results in T-PEMs, increased phosphorylation of STAT1 has been observed in TAMs (40) . 5 Kusmartsev and Gabrilovich have also described elevated STAT1 in TAMs, which they associate with an up-regulation of iNOS and arginase activity in these cells (41) . In this respect, we have reported that T-PEMs and TAMs in our tumor model have very low iNOS expression (12) , and in the present study, no differences in arginase production between N-PEMs and T-PEMs were observed (data not shown). This suggests a mixed phenotype displayed by T-PEMs, presenting some characteristics of M1 macrophages and only some of the M2-suppressive traits. Furthermore, the patterns of cytokine expression displayed by T-PEMs provide functional evidence that these cells are different from M1 and M2 macrophages. Remarkably, T-PEMs are not fixed in their mixed M1/M2 phenotype, and can become high producers of IL-12 or of IL-10. T-PEMs can be experimentally switched to express high amounts of IL-12p70 by culturing in the presence of LPS and IFN-g. Moreover, they can be induced to produce elevated amounts of IL-10 by culturing them with peptidoglycan, a Tolllike receptor 2 ligand (Supplemental Fig. S3) .
We sought to examine the possibility of enhanced apoptosis in T-PEMs, as a consequence of their decreased NFnB. Results indicate that resting T-PEMs express dramatically diminished levels of NFnB-induced antiapoptotic Bcl-x, enhanced activated caspase-3, and increased apoptosis. Importantly, apoptotic cells such as T-PEMs may still be PI À in early apoptotic stages and thus detected as ''viable'' macrophages due to intact membranes. To analyze whether apoptosis could induce the marrow of tumor-bearing mice to compensate for the loss of macrophages in the periphery by generating higher numbers of myeloid progenitor cells, bone marrow from normal and tumor-bearing mice were compared using CFU assays specific for committed myeloid progenitors. Our data show that the frequency of committed myeloid progenitors for either a broad spectrum of myeloid cell types (IL-3) or specific for the monocyte's/macrophage's lineage (M-CSF) are both significantly augmented in tumor-bearing mice. Increased myelopoiesis in the marrow of tumor-bearing mice has been associated with tumor factors (42, 43) . However, we show for the first time that a decrease in macrophage numbers, in the absence of a tumor, can also induce marrow myelopoiesis. Furthermore, macrophage-depleted mice show myelopoiesis which specifically replenishes cells of the macrophage lineage. Compensatory homeostasis due to increased macrophage apoptosis could be an additional contributing factor to the increased myelopoiesis observed in tumor bearers. The migration of newly produced monocytes from bone marrow to the circulation could result in macrophages with an immature phenotype. Thus, we compared the phenotype of T-PEMs with that of N-PEMs. Flow cytometry analysis revealed significantly decreased expression of F4/80, CD68, CD115, and CD11b in T-PEMs, all markers of macrophage differentiation. Interestingly, these cells express the granulocyte marker Gr-1 at higher levels than N-PEMs. Gr-1 is considered a marker of neutrophils and of immunosuppressive MDSC, which are CD11b + / Gr-1 + (44). CD68 + /Gr-1 + macrophages have been described in the peritoneal cavity of mice infected with low doses of Toxoplasma gondii; these macrophages also express CD11b and F4/80 but at lower levels than PEMs from uninfected mice (45) . Gr-1 is also expressed by immature TAMs thought to function in immunosuppression (46) . Our T-PEMs do not express characteristic markers of MDSC, such as arginase and/or nitric oxide (15) . In contrast to our T-PEMs, splenic MDSCs isolated from DA-3-tumor-bearing mice do not express F4/80 (47) . Our data suggest that T-PEMs are a less differentiated cell population and thus represent recently recruited monocytes from the blood that may become apoptotic during differentiation into macrophages. The fact that T-PEMs are less differentiated may also contribute to their highly plastic behavior.
We sought to determine whether tumor-derived factors were associated with the changes observed in T-PEMs. Our results show that factors secreted by DA-3 and LLC decreased NFnB and C/EBP expression in N-PEMs. Indeed, TGFh and PGE 2 , individually and additively induced down-regulation of NFnB and C/EBP family members. Interestingly, pretreatment with VEGF induced elevated levels of NFnB and C/EBP in N-PEMs, in sharp contrast to our data with T-PEMs. VEGF levels that circulate in tumor bearers may not be sufficient to increase NFnB and C/EBP in T-PEMs, or alternatively, VEGF might interact with other factors in vivo which block the induction of NFnB and C/EBP.
Tumors produce immunomodulatory factors in excess, which may thus alter immune function both locally at the tumor site and systemically. Reversing tumor-induced immune function in cancer patients may be carried out by targeting impaired immune cells.
One possibility is to re-educate M2 TAMs or mixed phenotype M1/M2 T-PEMs to become antitumor M1s. Augmenting NFnB expression may be one approach, as peripheral macrophages as well as TAMs from various tumor models exhibit down-regulated NFnB (48). 6 
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